Анализ результатов биопсий предстательной железы в лечебных учреждениях Екатеринбургa за 2000—2006 гг.

1. Матвеев Б.П. Клиническая онкоурология. М.; 2003. с. 435—44.

2. Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2005 г. Вестн РОНЦ им. Н.Н. Блохина РАМН. 2007; 18(2)(прил. 1):52—89.

3. Sakr W.A., Haas G.P., Cassin B.F. et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150:379—85.

4. Satariano W.A., Ragland K.E., Van Den Eeden S.K. Cause of death in men diagnosed with prostate carcinoma. Cancer 1998;83(6):1180—8.

5. Scardino P.T., Weaver R., Hudson A.L. Early detection of prostate cancer. Hum Pathol 1992; 23(3):211—22.

6. Coldman A.J., Phillips N., Pickles T.A. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. CMAJ 2003;168(1):31—5.

7. Holmberg L., Bill-Axelson A., Helgesen F. et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. NEJM 2002;347(11):781—9.

8. Albertsen P.C., Hanley J.A., Fine J. 20year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293(17):2095—101.

9. Pu Y.-S., Fujimoto H., Kakizoe T., Myers R. The 18th International Symposium: controversies in prostate cancer diagnosis and treatment. Jpn J Clin Oncol 2005;35(11):680—9.

10. Johansson J.-E., Andren O., Andersson S.-O. et al. Natural history of early, localized prostate cancer. JAMA 2004;291(22):2713—9.

11. Jemal A., Ward E., Wu X. et al. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States. Cancer Epidemiol Biomarkers Prev 2005;14(3):590—5.

12. Маринбах Е.Б. Рак предстательной железы. М.: Медицина; 1989.

13. Gann P.H., Hennekens C.H., Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 1995;273(4):289—94.

14. Keetch D.W., McMurtry J.M., Smith D.S. et al. Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies. J Urol 1996;156:428—31.

15. Presti J.C. Jr., Chang J.J., Bhargava V. et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 2000;163(1):163—6.

16. Stewart C.S., Leibovich B.C., Weaver A.L., Lieber M.M. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001;166(1):86——91.

17. Zackrisson B., Aus G., Bergdahl S. et al. The risk of finding focal cancer (less than 3 mm) remains high on rebiopsy of patients with persistently increased prostate specific antigen but the clinical significance is guestionable. J Urol 2004;171(4):1500—3.

18. Coley C.M., Barry M.J., Mulley A.G. Clinical guideline. Part III: Screening for prostate cancer. Ann Intern Med 1997;126(6):480—4.

19. Scherr D., Swindle P.R., Scardino P.T. National comprehensive cancer network guidelines for the management of prostate cancer. Urology 2003;61(Suppl 2A):14—24.

20. Brawer M.K. Screening for prostate cancer. Semin Surg Oncol 2000;18:29—36.

21. Roehrborn C.G., NcConnell J., Bonilla J. et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 2000;163(1):13—20.

22. Basler J.W., Thompson I.M. Lest we abandon digital rectal examination as a screening test for prostate cancer. J Natl Cancer Inst 1998;90(23):1761—3.

23. Thompson I.M., Pauler D.K., Goodman P.J. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter. N Engl J Med 2004;350(22):2239—46.

24. Graefen M., Karakiewicz P.I., Cagiannos I. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002;20(15):3206—12.

25. Karazanashvili G., Abrahamsson P.-A. Prostate specific antigen and human glandular kallikrein 2 in early detection of prostate cancer. J Urol 2003;169(2):445—57.

26. Scott R., Mutchnik D.L., Laskowski T.Z., Schmalhorst W.R. Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol 1969;101(4):602—7.

27. Вишневский А.Г. Население России 2003—2004. Одиннадцатый—двенадцатый ежегодный демографический доклад. М.: Наука; 2006.